Sun Yat-sen University

About: Sun Yat-sen University is a education organization based out in Guangzhou, Guangdong, China. It is known for research contribution in the topics: Population & Cancer. The organization has 115149 authors who have published 113763 publications receiving 2286465 citations. The organization is also known as: Zhongshan University & SYSU.

Directional Construction of Vertical Nitrogen-Doped 1T-2H MoSe2 /Graphene Shell/Core Nanoflake Arrays for Efficient Hydrogen Evolution Reaction.

Abstract: The low utilization of active sites and sluggish reaction kinetics of MoSe2 severely impede its commercial application as electrocatalyst for hydrogen evolution reaction (HER). To address these two issues, the first example of introducing 1T MoSe2 and N dopant into vertical 2H MoSe2/graphene shell/core nanoflake arrays that remarkably boost their HER activity is herein described. By means of the improved conductivity, rich catalytic active sites and highly accessible surface area as a result of the introduction of 1T MoSe2 and N doping as well as the unique structural features, the N-doped 1T-2H MoSe2/graphene (N-MoSe2/VG) shell/core nanoflake arrays show substantially enhanced HER activity. Remarkably, the N-MoSe2/VG nanoflakes exhibit a relatively low onset potential of 45 mV and overpotential of 98 mV (vs RHE) at 10 mA cm−2 with excellent long-term stability (no decay after 20 000 cycles), outperforming most of the recently reported Mo-based electrocatalysts. The success of improving the electrochemical performance via the introduction of 1T phase and N dopant offers new opportunities in the development of high-performance MoSe2-based electrodes for other energy-related applications.

White‐Light Emission Strategy of a Single Organic Compound with Aggregation‐Induced Emission and Delayed Fluorescence Properties

Abstract: A novel white-light-emitting organic molecule, which consists of carbazolyl- and phenothiazinyl-substituted benzophenone (OPC) and exhibits aggregation-induced emission-delayed fluorescence (AIE-DF) and mechanofluorochromic properties was synthesized. The CIE color coordinates of OPC were directly measured with a non-doped powder, which presented white-emission coordinates (0.33, 0.33) at 244 K to 252 K and (0.35, 0.35) at 298 K. The asymmetric donor–acceptor–donor′ (D-A-D′) type of OPC exhibits an accurate inherited relationship from dicarbazolyl-substituted benzophenone (O2C, D-A-D) and diphenothiazinyl-substituted benzophenone (O2P, D′-A-D′). By purposefully selecting the two parent molecules, that is, O2C (blue) and O2P (yellow), the white-light emission of OPC can be achieved in a single molecule. This finding provides a feasible molecular strategy to design new AIE-DF white-light-emitting organic molecules.

The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells

Abstract: The polycomb group protein B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) is dysregulated in various cancers, and its upregulation strongly correlates with an invasive phenotype and poor prognosis in patients with nasopharyngeal carcinomas. However, the underlying mechanism of Bmi-1-mediated invasiveness remains unknown. In the current study, we found that upregulation of Bmi-1 induced epithelial-mesenchymal transition (EMT) and enhanced the motility and invasiveness of human nasopharyngeal epithelial cells, whereas silencing endogenous Bmi-1 expression reversed EMT and reduced motility. Furthermore, upregulation of Bmi-1 led to the stabilization of Snail, a transcriptional repressor associated with EMT, via modulation of PI3K/Akt/GSK-3beta signaling. Chromatin immunoprecipitation assays revealed that Bmi-1 transcriptionally downregulated expression of the tumor suppressor PTEN in tumor cells through direct association with the PTEN locus. This in vitro analysis was consistent with the statistical inverse correlation detected between Bmi-1 and PTEN expression in a cohort of human nasopharyngeal carcinoma biopsies. Moreover, ablation of PTEN expression partially rescued the migratory/invasive phenotype of Bmi-1-silenced cells, indicating that PTEN might be a major mediator of Bmi-1-induced EMT. Our results provide functional and mechanistic links between the oncoprotein Bmi-1 and the tumor suppressor PTEN in the development and progression of cancer.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Abstract: Summary Background Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosine kinases. In a randomised phase 2 study in patients with previously treated non-small-cell lung cancer (NSCLC), adding vandetanib 100 mg to docetaxel significantly improved progression-free survival (PFS) compared with docetaxel alone, including a longer PFS in women. These results supported investigation of the combination in this larger, definitive phase 3 trial (ZODIAC). Methods Between May, 2006, and April, 2008, patients with locally advanced or metastatic (stage IIIB–IV) NSCLC after progression following first-line chemotherapy were randomly assigned 1:1 through a third-party interactive voice system to receive vandetanib (100 mg/day) plus docetaxel (75 mg/m 2 intravenously every 21 days; maximum six cycles) or placebo plus docetaxel. The primary objective was comparison of PFS between the two groups in the intention-to-treat population. Women were a coprimary analysis population. This study has been completed and is registered with ClinicalTrials.gov, number NCT00312377. Findings 1391 patients received vandetanib plus docetaxel (n=694 [197 women]) or placebo plus docetaxel (n=697 [224 women]). Vandetanib plus docetaxel led to a significant improvement in PFS versus placebo plus docetaxel (hazard ratio [HR] 0·79, 97·58% CI 0·70–0·90; p vs 7/690 [1%]), neutropenia (199/689 [29%] vs 164/690 [24%]), leukopenia (99/689 [14%] vs 77/690 [11%]), and febrile neutropenia (61/689 [9%] vs 48/690 [7%]) were more common with vandetanib plus docetaxel than with placebo plus docetaxel. The most common serious adverse event was febrile neutropenia (46/689 [7%] in the vandetanib group vs 38/690 [6%] in the placebo group). Interpretation The addition of vandetanib to docetaxel provides a significant improvement in PFS in patients with advanced NSCLC after progression following first-line therapy. Funding AstraZeneca.